To examine the possible clinical relevance of CDC20 in breast cancer development and drug resistance, we measured the protein expression levels of CDC20 in the normal breast epithelial (MCF-10A), the ductal carcinoma in situ (DCIS), and different breast cancer cell lines, including TNBC, HER2+, and Luminal subtypes (Figure 1a). This evidence concerns the gene CDC20 and breast carcinoma.